Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 5/12/20 → 5/2/24 |
Funding
- Servier Pharmaceuticals LLC: $138,789.00
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (AG881-C-004)
- Villano, John (PI)